Dr Reddy (REDY.BO): Investor Call Update: API Impurity Delays Semaglutide Ramp

研报英文原文证据摘录

Dr Reddy (REDY.BO): Investor Call Update: API Impurity Delays Semaglutide Ramp

Dr Reddy (REDY.BO)

09 July 2026 Citi Research

investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but

investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from

the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from

the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the

Product in the United States. Any orders by US investors resulting from the information contained in the Product may be

placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first

named author is employed by.

The Product is made available in Australia through Citigroup Global Markets Australia Pty Limited. (ABN 64 003 114 832 and

AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission.

Citigroup Centre, 2 Park Street, Sydney, NSW 2000. Citigroup Global Markets Australia Pty Limited is not an Authorised

Deposit-Taking Institution under the Banking Act 1959, nor is it regulated by the Australian Prudential Regulation Authority.

The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão

de Valores Mobiliários ("CVM"), BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de

Investimento do Mercado de Capitais and ANBIMA – Associação Brasileira das Entidades dos Mercados Financeiro e de

Capitais.